Key facts
- This page summarizes Justin Zamirowski's Form 4 filing for Better Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Jun 2022, 16:47.
Justin Zamirowski - 27 May 2022 Form 4 Insider Report for Better Therapeutics, Inc.
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 27 May 2022
- Net transaction value
- +$838
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2022, 16:47:11 UTC
- Prior SEC filing
- 18 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Heinen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Justin Zamirowski filed Form 4 for Better Therapeutics, Inc. on 01 Jun 2022.
Change
- Previous filing in this sequence was filed on 18 May 2022.
- Current net transaction value: +$838.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTTX
transaction
Common Stock
Options Exercise
- Transaction value
- $838
- Shares
- +1,677
- Change %
- +4.8%
- Price
- $0.5000
- Shares after
- 36,913
- Date
- 27 May 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,677
- Change %
- -3.7%
- Price
- $0.000000
- Shares after
- 43,626
- Date
- 27 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,677
- Exercise price
- $0.5000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Justin Zamirowski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The Assumed Option (as defined in the Agreement and Plan of Merger, dated April 6, 2021, as amended, by and among Mountain Crest Acquisition Corp. II, MCAD Merger Sub Inc. and Better Therapeutics, Inc.) vests as to 1/4th of the shares subject to the Assumed Option on July 27, 2021 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The Assumed Option was granted on August 14, 2020.